Biosimilar advancements are improving access in the Neupogen Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Neupogen (filgrastim) Market At The End Of The 2026–2030 Forecast Period?

The neupogen (filgrastim) market size has experienced robust growth in recent years. It is projected to increase from $1.4 million in 2025 to $1.48 million in 2026, at a compound annual growth rate (CAGR) of 5.5%. The expansion witnessed in the historic period is attributable to an increase in chemotherapy utilization, the high infection risk among neutropenic patients, the clinical validation of g-csf therapy, hospital-centered cancer care practices, and the limited availability of early treatment options.

The neupogen (filgrastim) market is anticipated to experience significant expansion over the coming years, with its size projected to reach $1.81 million by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. This expected growth throughout the forecast period is primarily attributed to factors such as the increasing incidence of cancer, the wider adoption of biosimilars, the expansion of outpatient oncology services, improved access to biologic therapies, and a concentrated focus on infection prevention. Additionally, major trends during this period are expected to include the rising implementation of supportive care in oncology, the broadened management of chemotherapy-induced neutropenia, increased uptake of biologic growth factors, a shift towards outpatient neutropenia treatment, and the growing availability and use of biosimilar alternatives.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What Primary Drivers Are Shaping The Development Of The Neupogen (filgrastim) Market?

An escalating incidence of various diseases is anticipated to fuel the expansion of the neupogen (filgrastim) market moving forward. Diseases represent functional or structural irregularities in the body, manifesting distinct symptoms or affecting specific areas, often stemming from infections, genetic predispositions, environmental factors, or lifestyle choices. The rising occurrence of diverse diseases is propelled by factors such as aging demographics, sedentary lifestyles, increasing pollution levels, suboptimal dietary habits, and the global dissemination of infectious pathogens. Neupogen (filgrastim) effectively manages the complications of neutropenia induced by chemotherapy by stimulating the creation of neutrophils, thereby bolstering the immune system’s capacity to combat infections in patients with compromised immunity. Its role is vital in reducing hospitalizations, mitigating infection risks, and facilitating continuous cancer treatment plans for individuals undergoing intensive therapies. For instance, in April 2024, Allergy UK, a UK-based national charity, reported that over 21 million people in the UK are affected by allergies, which became the most frequently cited chronic health condition in 2022, with forecasts indicating that by 2026, half of Europe’s population will experience at least one allergy. Additionally, in June 2022, data from Macmillan Cancer Support, a UK-based cancer charity, showed that the number of individuals living with cancer reached 3 million in 2022 and is projected to increase to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Consequently, the increasing prevalence of various diseases is a significant driver for the growth of the neupogen (filgrastim) market.

What Segment Types Make Up The Neupogen (filgrastim) Market?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Market Trends Are Creating New Opportunities In The Neupogen (filgrastim) Market?

Companies operating within the neupogen (filgrastim) market are increasingly focused on developing innovative filgrastim biosimilar products to offer a cost-effective and accessible option for treating chemotherapy-induced neutropenia. Filgrastim biosimilars are biological medications that closely mirror the original filgrastim (Neupogen) regarding safety, efficacy, and structure, primarily utilized to stimulate neutrophil production in patients receiving chemotherapy to prevent neutropenia. For instance, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi was one of three biosimilars cleared by the FDA on the same day, contributing to a cumulative total of 55 biosimilars approved in the United States as of June 2024. It is indicated for lowering the incidence of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer drugs.

Who Are The Key Players Driving Competition In The Neupogen (filgrastim) Market?

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Read the full neupogen (filgrastim) market report here:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

How Does The Neupogen (filgrastim) Market Perform Across Major Global Regions?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neupogen (filgrastim) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp

Browse Through More Reports Similar to the Global Neupogen (filgrastim) Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795